(Q84950112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Results of the IDEAL trial: "Mirror, mirror on the wall ... which's the fairest peg-interferon of them all?" (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Julian Schulze Zur Wiesch

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ansgar W Lohse

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

2034-2037

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

Diagnosis, management, and treatment of hepatitis C: an update

12 February 2020

cites work

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

1 reference

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

7 January 2021

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

7 January 2021

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

7 January 2021

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

7 January 2021

Translating statistical findings into plain English

1 reference

7 January 2021

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

7 January 2021

A step forward in therapy for hepatitis C.

1 reference

7 January 2021

Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection

1 reference

7 January 2021

Future trends in managing hepatitis C.

1 reference

7 January 2021

When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection

1 reference

7 January 2021

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial

1 reference

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19937677%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference